Table 1.
Distribution of clinicopathologic characteristics
| Factor | BCT (n = 224) | Mastectomy (n = 327) | P value |
|---|---|---|---|
| Age | 0.4 | ||
| Median | 51 | 50 | |
| Range | 28–76 | 24–80 | |
| Clinical tumor size (cm) (mean) | 3.42 | 4.62 | <0.001 |
| Clinical stage | <0.001 | ||
| I | 13 (6%) | 8 (2%) | |
| II | 160 (71%) | 140 (43%) | |
| III | 51 (23%) | 179 (55%) | |
| Histology | <0.01 | ||
| IDC | 201 (90%) | 255 (78%) | |
| ILC | 7 (3%) | 35 (11%) | |
| Mixed IDC/ILC | 11 (5%) | 29 (9%) | |
| Other | 5 (2%) | 8 (2%) | |
| Grade | 0.07 | ||
| I | 9 (4%) | 19 (6%) | |
| II | 64 (29%) | 120 (37%) | |
| III | 150 (67%) | 188 (57%) | |
| Unknown | 1 (<1%) | 0 | |
| ER | <0.01 | ||
| Positive | 131 (58%) | 230 (70%) | |
| Negative | 93 (42%) | 97 (30%) | |
| PR | 0.10 | ||
| Positive | 102 (46%) | 172 (53%) | |
| Negative | 122 (54%) | 155 (47%) | |
| HER | 0.22 | ||
| Positive | 27 (12%) | 52 (16%) | |
| Negative | 194 (87%) | 273 (83%) | |
| Unknown | 3 (1%) | 2 (1%) | |
| Margin status | 0.04 | ||
| Negative | 209 (93%) | 316 (97%) | |
| Close (<2 mm)a | 14 (6%) | 6 (2%) | |
| Positive | 1 (<1%) | 5 (1%) | |
| Residual tumor size (cm) | <0.001 | ||
| 0 | 22 (10%) | 25 (8%) | |
| 0–2 | 144 (64%) | 118 (36%) | |
| >2 | 58 (26%) | 184 (56%) | |
| Positive lymph nodes | <0.001 | ||
| 0 | 126 (56%) | 67 (20%) | |
| 1–3 | 58 (26%) | 101 (31%) | |
| 4–9 | 28 (13%) | 98 (30%) | |
| ≥10 | 12 (5%) | 61 (19%) | <0.001 |
ER estrogen receptor, PR progesterone receptor
a
Close included invasive cancer or ductal carcinoma in situ within 2 mm of the margin